🔗 Share this article

While the US undertakes unprecedented revisions to its immunization guidelines, one figure has surfaced in a surprising turn: Tracy Beth Høeg, a US-based sports physician and public health researcher who rose to prominence by questioning coronavirus vaccines during the global health crisis and has focused upon alleged fatalities following Covid immunization in her brief position at the US Food and Drug Administration (FDA).

Planned Changes to Pediatric Vaccine Schedule

Agency leaders planned to unveil major changes to the pediatric vaccination calendar in December, bringing the US with Denmark’s national calendar, it is understood – a substantial departure that would put the US at odds with many the global community with no evidence for public health gain. The announcement has been postponed until the coming year.

Rather than the top vaccines chief, Dr. Høeg is listed to address the audience at the gathering. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth appointee to run the division this year.

A New Direction at the Agency

The acting appointment could signify a tighter collaboration between the drug and vaccine branches as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it suggests a renewed priority upon rolling back long-standing immunizations at the FDA.

Høeg has often pushed for halting certain pediatric shot schedules in the US to become more like the Danish model, a country with comprehensive healthcare and a number of inhabitants roughly the size of the state of Wisconsin.

To date comments, she has persisted in emphasizing on immunizations – usually the responsibility of Prasad, chief of the FDA’s vaccine center – as opposed to medication approval.

Doubts Over Qualifications

Dr. Høeg has no obvious background in medication creation, regulation or management, which has been customary for previous directors of the CBER. She has worked at the FDA as a senior adviser to the agency head and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for leading the drug-regulation department, stated a neurologist and psychiatrist. “She lacks experience running a scientific study. She lacks experience in managing a large organization. She is not an expert in drug approvals.”

Previous commissioners of the center would “grasp legal statutes and the science of drug development”, noted a former acting FDA commissioner. “Clearly, she doesn’t have the type of experience that former directors who headed CBER have had.”

This division has an immense portfolio at the FDA, Woodcock stated.

“The public just focuses on the new drug program, but the generic drug division authorizes a multitude of generic drugs. There’s a biologic copycat branch, over-the-counter program and so forth, and all of those have to be supervised,” Dr. Woodcock noted. “The area you neglect, that is the part that I always told people is going to bite you.”

Additionally, a substantial management aspect to the position, which supervises more than 5,000 staff members. “It’s a enormous administrative position, if you perform it correctly,” the former official added.

Agency Reaction and Contentious Initiatives

Regarding inquiries about Dr. Høeg's qualifications and whether this appointment signifies greater collaboration among FDA leaders on immunizations, a representative said that the “inquiries are based on flawed assumptions”.

“Her resume aligns with the functions of her position,” the official said, noting the months Dr. Høeg spent guiding the FDA commissioner on “medication safety and approval science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the agency head's recently launched fast-track approval initiative, a controversial one-day drug-approval program that apparently concerned her former heads. “By what process are these medications being picked for this expedited pathway? Who is making the decisions?” Dr. Howard said. “There’s a lot of secrecy going on at the agency right now.”

Overall, he remarked, “the FDA looks to be trending towards laxer rules of most medications, aside from immunizations.”

Documented History on Immunizations

With immunizations, Høeg has a clearer, if troubling, history, critics have noted. She published a research paper using non-validated volunteer-provided data to determine the rate of heart inflammation following Covid vaccination. She advised the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccines are pose a greater threat than they are.

Among her “policy goals” for the incoming federal leadership featured changing rules for novel immunizations and discontinuing “optional” immunizations, she remarked post-election on a podcast. At the FDA, Dr. Høeg has reportedly floated the idea of barring adolescent males from receiving COVID-19 vaccinations.

“She’s an complete ideologue who commences with her beliefs and tailors the evidence to accommodate the science in a extremely misleading, fraudulent way,” Howard said.

Gaining Influence and a “Campaign of Retribution”

Høeg became part of other skeptics, {like|